Atossa Therapeutics (ATOS) Fundamental Analysis: Revenue, Earnings & Valuation

7.13 / 10

Outperform

Fundamentals are rated Outperform (7.1/10). Strengths include high accounts‑receivable turnover, solid interest coverage, and robust asset‑MV differentials. Weak points are low fixed‑asset turnover and zero income‑tax ratio. Overall metrics suggest solid financial health.

Analysis Checks(8/10)

Revenue-MV

Value-0.28

Score3/3

Weight30.61%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value78.05

Score2/3

Weight1.63%

1M Return0.58%

Inventory turnover ratio

Value47.57

Score3/3

Weight-1.74%

1M Return-0.67%

Accounts receivable turnover ratio

Value25.89

Score2/3

Weight-1.72%

1M Return-0.65%

PB-ROE

Value0.87

Score2/3

Weight34.32%

1M Return8.98%

Income tax / Total profit (%)

Value0.00

Score0/3

Weight-3.91%

1M Return-1.54%

Fixed assets turnover ratio

Value7899.90

Score1/3

Weight-3.23%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-1.94%

1M Return-0.73%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-1.91%

1M Return-0.74%

Asset-MV

Value-0.48

Score3/3

Weight47.89%

1M Return13.09%

Is ATOS undervalued or overvalued?

ATOS scores 7.13/10 on fundamentals and holds a Discounted valuation at present. Backed by its -62.74% ROE, 0.00% net margin, -1.17 P/E ratio, 1.03 P/B ratio, and -32.89% earnings growth, these metrics solidify its Outperform investment rating.